Nevro’s product is now the only spinal cord stimulation system labeled to treat the condition, the company said.
The FDA approval came after the company conducted a 12-month study into its system’s treatment of back pain. The company said study participants saw improvements in pain relief, quality of life and a reduction in daily opioid use compared to conventional treatments.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.